metricas
covid
Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Quality of life in patients with non-muscle invasive bladder tumor undergoing ad...
Journal Information
Vol. 47. Issue 6.
Pages 360-368 (July - August 2023)
Share
Share
Download PDF
More article options
Vol. 47. Issue 6.
Pages 360-368 (July - August 2023)
Original article
Quality of life in patients with non-muscle invasive bladder tumor undergoing adjuvant intravesical treatment
Calidad de vida en pacientes con tumor vesical no músculo-invasivo sometidos a tratamiento adyuvante intravesical
J. Panach-Navarrete
Corresponding author
jorge.panach@uv.es

Corresponding author.
, A. Devís-Peiró, M.A. Lloret-Durà, S. Sánchez-Gimeno, E. Murcia-Díez, J.M. Martínez-Jabaloyas
Department of Urology, University Clinic Hospital of Valencia, INCLIVA, Instituto de Investigación Sanitaria, Facultat de Medicina i Odontologia, Universitat de València, Valencia, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (5)
Table 1. Baseline characteristics of the sample.
Table 2. Differences in physical, mental, and urinary quality of life at each time point between patients on BCG and MMC treatment.
Table 3. Changes in the physical, mental, and urinary quality of life of patients on BCG treatment between the different time points studied.
Table 4. Changes in physical, mental, and urinary quality of life of patients under treatment with MMC at the different time points studied.
Table 5. Changes in urinary quality of life in patients undergoing treatment with MMC with pairwise analysis of the different time points studied.
Show moreShow less
Abstract
Introduction

The objective of the study was to establish a possible relationship between mitomycin-C (MMC) and bacillus Calmette-Guérin (BCG) treatments and quality of life impairment.

Material and Methods

Quasi-experimental, prospective, and longitudinal study including patients undergoing adjuvant treatment in NMIBC. The Short form-12 (SF-12) and Urogenital Distress Inventory-6 (UDI-6) questionnaires were used to measure quality of life. Questionnaire scores were compared between cases with MMC and BCG before induction (M1), at 4 weeks (M2) and at 2 months (M3).

Results

Of the 90 patients enrolled, 54 were in the BCG group and 36 in the MMC group. It was found that BCG patients had worse perceived physical quality of life compared to MMC patients in M2 (OR:2.59, p=0.046). In addition, significant changes were found in the urinary quality of life of patients on MMC treatment between the different time points (UDI-6 score: 33.33 in M1, 27.78 in M2 and 16.67 in M3, p=0.001).

Conclusions

There are no differences in urinary quality of life between patients treated with MMC and BCG. Patients with MMC show a significant recovery of urinary quality of life from the completion of the induction course, which becomes even more significant after 2 months. In addition, BCG-treated patients have worse physical quality of life after 4 weeks of treatment than those treated with MMC.

Keywords:
Bladder tumor
Quality of life
Adjuvant therapy
Mitomycin
BCG
Resumen
Introducción

El objetivo del estudio fue establecer posible relación entre los tratamientos con mitomicina-C (MMC) y bacilo de Calmette-Guérin (BCG) y la afectación en la calidad de vida-

Material y métodos

Estudio cuasiexperimental, prospectivo y longitudinal, recogiendo pacientes sometidos a tratamiento adyuvante en TVNMI. Se utilizaron los cuestionarios Short form-12 (SF-12) y Urogenital Distress Inventory-6 (UDI-6) para medir la calidad de vida. Se compararon las puntuaciones de los cuestionarios entre casos con MMC y BCG antes de iniciar la inducción (M1), a las 4 semanas (M2) y a los dos meses (M3).

Resultados

Se recogieron 90 pacientes, 54 en el grupo de BCG y 36 en el de MMC. Se comprobó que los pacientes con BCG percibían peor calidad de vida física comparados con los de MMC en M2 (OR: 2,59, p = 0,046). Además, se hallaron cambios significativos en la calidad de vida urinaria de los pacientes en tratamiento con MMC entre los diferentes momentos temporales (puntuación del UDI-6: 33,33 en M1, 27,78 en M2 y 16,67 en M3, p=0,001)

Conclusiones

No existen diferencias en la calidad de vida urinaria entre los pacientes tratados con MMC y BCG. Los pacientes con MMC muestran una recuperación significativa de la calidad de vida urinaria a partir de la finalización de la inducción, que aumenta aún más a los dos meses de la misma. Además, los pacientes tratados con BCG presentan peor calidad de vida física a las 4 semanas de tratamiento que aquellos tratados con MMC.

Palabras clave:
Tumor vesical
Calidad de vida
Adyuvancia
Mitomicina
BCG

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos